Ko J, Weil A, Maxwell L, Kitao T, Haydon T (2007) Plasma concentrations of lidocaine in dogs
following lidocaine patch application. J Am Anim Hosp Assoc 43:280–283
Ko JC, Maxwell LK, Abbo LA, Weil AB (2008) Pharmacokinetics of lidocaine following the
application of 5% lidocaine patches to cats. J Vet Pharmacol Ther 31:359–367
Kyles AE, Papich M, Hardie EM (1996) Disposition of transdermally-administered fentanyl in
dogs. Am J Vet Res 57:715–719
Laffont CM, Bousquet-Me ́lou A, Bralet D, Alvinerie M, Fink-Gremmels J, Toutain PL (2003)
A pharmacokinetic model to document the actual disposition of topical ivermectin in cattle.
Vet Res 34:445–460
Lavy E, Steinman A, Soback S (2006) Oral controlled-release formulation in veterinary medicine.
Crit Rev Drug Carrier Syst 23:165–204
Leavell S, Wright B, Scappino L, Sirriyah J, Chen C, Clements JD, Burkhard MJ (2005) Induction
of serum and mucosal FIV-specific immune responses by intranasal immunization with
p24Gag. Vaccine 23:1471–1478
Lespine A, Alvinerie M, Vercruysse J, Prichard RK, Geldhof P (2008) ABC transporter modula-
tion: a strategy to enhance the activity of macrocyclic lactone anthelmintics. Trends Parasitol
24:293–298
Li M, Yuan H, Li N, Song G, Zheng Y, Baratta M, Hua F, Thurston A, Wang J, Lai Y (2008)
Identification of interspecies difference in efflux transporters of hepatocytes from dog, rat,
monkey and human. Eur J Pharm Sci 35:114–126
Lok JB, Knight DH, Nolan TJ, Grubbs ST, Cleale RM, Heaney K (2005) Efficacy of an injectable,
sustained-release formulation of moxidectin in preventing experimental heartworm infection
in mongrel dogs challenged 12 months after administration. Vet Parasitol 128:129–135
Lo ̈scher W, Potschka H (2005) Drug resistance in brain diseases and the role of drug efflux
transporters. Nat Rev Neurosci 6:591–602
Lui CY, Amidon GL, Goldberg A (1991) Intranasal absorption of flurazepam, midazolam and
triazolam in dogs. J Pharm Sci 80:1125–1129
Luna-Torto ́s C, Fedrowitz M, Lo ̈scher W (2008) Several major antiepileptic drugs are substrates
for human P-glycoprotein. Neuropharmacology 55:1364–1375
Ma L, Pratt SE, Cao J, Dantzig AH, Moore RE, Slapak CA (2002) Identification and characteriza-
tion of the canine multidrug resistance-associated protein. Mol Cancer Ther 1:1335–1342
Makhey VD, Guo A, Norris DA, Hu P, Yan J, Sinko PJ (1998) Characterization of the regional
intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells. Pharm Res
15:1160–1167
Malavasi LM, Nyman G, Augustsson H, Jacobson M, Jensen-Waern M (2006) Effects of epidural
morphine and transdermal fentanyl analgesia on physiology and behaviour after abdominal
surgery in pigs. Lab Anim 40:16–27
Martinez M, Modric S, Sharkey M, Troutman L, Walker L, Mealey K (2008a) The pharmacoge-
nomics of P-glycoprotein and its role in veterinary medicine. J Vet Pharmacol Ther
31:285–300
Martinez M, Rathbone M, Burgess D, Huynh M (2008b)In vitroandin vivoconsiderations
associated with parenteral sustained release products: a review based upon information pre-
sented and points expressed at the 2007 Controlled Release Society Annual Meeting. J Control
Release 129:79–87
Matschke C, Isele U, van Hoogevest P, Fahr A (2002) Sustained-release injectables formedin situ
and their potential use for veterinary products. J Control Release 85:1–15
McConnel CS, House JK (2007) Infectious bovine keratoconjunctivitis antimicrobial therapy.
Aust Vet J 85:65–69
Mealey KL (2004) Therapeutic implications of the MDR-1 gene. J Vet Pharmacol Ther 27:257–264
Mealey KL (2008) Canine ABCB1 and macrocyclic lactones: heartworm prevention and pharma-
cogenetics. Vet Parasitol 158:215–222
Mealey KL, Bentjen SA, Gay JM, Cantor GH (2001) Ivermectin sensitivity in Collies is associated
with a deletion mutation of themdr1gene. Pharmacogenetics 11:727–733
108 D.J. Brayden et al.